Reports Q4 revenue $160.3M, consensus $72.68M. "Arcturus has continued to make remarkable operational and pipeline progress. This was recently exemplified by the completion of the initial objectives with our partnered COVID-19 and Flu vaccine programs with CSL," said Joseph Payne, President and CEO of Arcturus Therapeutics. "We are also pleased to report the completion of full enrollment ahead of schedule in the Phase 3 study being conducted by Meiji Pharma to evaluate ARCT-154 as a booster vaccine for COVID-19."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARCT:
